Receiving three doses of inactivated or mRNA COVID-19 vaccines was associated with lower odds of long COVID symptoms among people with a history of SARS-CoV-2 infection in Hong Kong, China: a cross-sectional survey study.

Publication date: Dec 11, 2024

High prevalence of long COVID symptoms has emerged as a significant public health concern. This study investigated the associations between three doses of COVID-19 vaccines and the presence of any and ≥3 types of long COVID symptoms among people with a history of SARS-CoV-2 infection in Hong Kong, China. This is a secondary analysis of a cross-sectional online survey among Hong Kong adult residents conducted between June and August 2022. This analysis was based on a sub-sample of 1,542 participants with confirmed SARS-CoV-2 infection during the fifth wave of COVID-19 outbreak in Hong Kong (December 2021 to April 2022). Among the participants, 40. 9% and 16. 1% self-reported having any and ≥3 types of long COVID symptoms, respectively. After adjusting for significant variables related to sociodemographic characteristics, health conditions and lifestyles, and SARS-CoV-2 infection, receiving at least three doses of COVID-19 vaccines was associated with lower odds of reporting any long COVID symptoms comparing to receiving two doses (adjusted odds ratio [AOR]: 0. 69, 95% CI: 0. 54, 0. 87, P = . 002). Three doses of inactivated and mRNA vaccines had similar protective effects against long COVID symptoms. It is important to strengthen the coverage of COVID-19 vaccination booster doses, even in the post-pandemic era.

Concepts Keywords
April Adolescent
China Adult
Pandemic Aged
Vaccination booster
COVID-19
COVID-19 Vaccines
COVID-19 Vaccines
Cross-Sectional Studies
Female
Hong Kong
Humans
inactivated vaccines
Long COVID
Male
Middle Aged
mRNA Vaccines
mRNA Vaccines
mRNA vaccines
post-COVID-19 condition
SARS-CoV-2
vaccination
Vaccines, Inactivated
Vaccines, Inactivated
Young Adult

Semantics

Type Source Name
disease MESH long COVID
disease IDO history
disease MESH SARS-CoV-2 infection
pathway REACTOME SARS-CoV-2 Infection
disease MESH lifestyles

Original Article

(Visited 1 times, 1 visits today)